Teduglutide ([Gly2]GLP-2) protects small intestinal stem cells from radiation damage.

Booth C, Booth D, Williamson S, Demchyshyn LL, Potten CS

Cell proliferation1 Dec 2004Cited by 67 (Europe PMC)

PMID15548172PMCIDPMC6495530DOI10.1111/j.1365-2184.2004.00320.xPepBankPUB-15548172

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study7

7 results from studies that gave the peptide. No result from this study comes from people.

01AnimalAnimal study (in vivo)Efficacy outcome
In CD1 and BDF1 mice, teduglutide demonstrated intestinotrophic effects.
In plain wordsIn mice of CD1 and BDF1 strains, teduglutide promoted intestinal growth.
Peptide
Teduglutide
Outcome
IncreaseIntestinotrophic effects
Study
mousen: not reported in source
CD1 and BDF1 mice
Outcome group
Gastrointestinal protection · Gastrointestinal
Studied dose
Dose not stated
Source sentences
Summary
Teduglutide demonstrated intestinotrophic effects in both CD1 and BDF1 mouse strains.
1 context sentence(design, population, supporting numbers)
Summary · context
A study was initiated to investigate the protective effects of teduglutide on the murine small intestinal epithelium following gamma-irradiation using the crypt microcolony assay as a measure of stem cell survival and functional competence.
Report a problemFND-1554817201
02AnimalAnimal study (in vivo)Efficacy outcome
In BDF1 mice, teduglutide increased intestinal weight by 28%.
In plain wordsIn BDF1 mice, teduglutide increased intestinal weight by 28%.
Peptide
Teduglutide
Outcome
IncreaseIntestinal weight
Study
mousen: not reported in source
BDF1 mice
Outcome group
Gastrointestinal protection · Gastrointestinal
Studied dose
0.2 mg/kg/day, b.i.d. · subcutaneous · 14 daysAs given in this study (mouse).
Measurements
Intestinal weight increase
28%
teduglutide
Source sentences
Summary
In BDF1 mice, subcutaneous injection of GLP-2 or teduglutide (0.2 mg/kg/day, b.i.d.) for 14 days increased intestinal weight by 28% and resulted in comparable increases in crypt size, villus height and area.
1 context sentence(design, population, supporting numbers)
Summary · context
A study was initiated to investigate the protective effects of teduglutide on the murine small intestinal epithelium following gamma-irradiation using the crypt microcolony assay as a measure of stem cell survival and functional competence.
Report a problemFND-1554817202
03AnimalAnimal study (in vivo)Efficacy outcome
In BDF1 mice, teduglutide increased crypt size, with increases comparable to GLP-2.
In plain wordsIn BDF1 mice, teduglutide increased intestinal crypt size, with increases comparable to GLP-2.
Peptide
Teduglutide
Outcome
IncreaseCrypt size
Study
mousen: not reported in source
BDF1 mice
Outcome group
Gastrointestinal protection · Gastrointestinal
Studied dose
0.2 mg/kg/day, b.i.d. · subcutaneous · 14 daysAs given in this study (mouse).
Source sentences
Summary
In BDF1 mice, subcutaneous injection of GLP-2 or teduglutide (0.2 mg/kg/day, b.i.d.) for 14 days increased intestinal weight by 28% and resulted in comparable increases in crypt size, villus height and area.
1 context sentence(design, population, supporting numbers)
Summary · context
A study was initiated to investigate the protective effects of teduglutide on the murine small intestinal epithelium following gamma-irradiation using the crypt microcolony assay as a measure of stem cell survival and functional competence.
Report a problemFND-1554817203
04AnimalAnimal study (in vivo)Efficacy outcome
In BDF1 mice, teduglutide increased villus height, with increases comparable to GLP-2.
In plain wordsIn BDF1 mice, teduglutide increased intestinal villus height, with increases comparable to GLP-2.
Peptide
Teduglutide
Outcome
IncreaseVillus height
Study
mousen: not reported in source
BDF1 mice
Outcome group
Gastrointestinal protection · Gastrointestinal
Studied dose
0.2 mg/kg/day, b.i.d. · subcutaneous · 14 daysAs given in this study (mouse).
Source sentences
Summary
In BDF1 mice, subcutaneous injection of GLP-2 or teduglutide (0.2 mg/kg/day, b.i.d.) for 14 days increased intestinal weight by 28% and resulted in comparable increases in crypt size, villus height and area.
1 context sentence(design, population, supporting numbers)
Summary · context
A study was initiated to investigate the protective effects of teduglutide on the murine small intestinal epithelium following gamma-irradiation using the crypt microcolony assay as a measure of stem cell survival and functional competence.
Report a problemFND-1554817204
05AnimalAnimal study (in vivo)Efficacy outcome
In BDF1 mice, teduglutide increased villus area, with increases comparable to GLP-2.
In plain wordsIn BDF1 mice, teduglutide increased intestinal villus area, with increases comparable to GLP-2.
Peptide
Teduglutide
Outcome
IncreaseVillus area
Study
mousen: not reported in source
BDF1 mice
Outcome group
Gastrointestinal protection · Gastrointestinal
Studied dose
0.2 mg/kg/day, b.i.d. · subcutaneous · 14 daysAs given in this study (mouse).
Source sentences
Summary
In BDF1 mice, subcutaneous injection of GLP-2 or teduglutide (0.2 mg/kg/day, b.i.d.) for 14 days increased intestinal weight by 28% and resulted in comparable increases in crypt size, villus height and area.
1 context sentence(design, population, supporting numbers)
Summary · context
A study was initiated to investigate the protective effects of teduglutide on the murine small intestinal epithelium following gamma-irradiation using the crypt microcolony assay as a measure of stem cell survival and functional competence.
Report a problemFND-1554817205
06AnimalAnimal study (in vivo)Efficacy outcome
In irradiated mice, teduglutide before irradiation significantly increased crypt stem cell survival versus vehicle, with protection factors from 1.3 to 1.5.
In plain wordsIn irradiated mice, teduglutide before irradiation increased intestinal stem cell survival versus vehicle.
Peptide
Teduglutide
Outcome
IncreaseCrypt stem cell survival
Study
mousen: not reported in source
Gamma-irradiated mice
Comparator
vehicle-treated controls
Outcome group
Gastrointestinal protection · Gastrointestinal
Studied dose
Dose not stated · 6 or 14 days before irradiationAs given in this study (mouse).
Measurements
Protection factor
1.3 to 1.5
range of doses
Source sentences
Summary
Teduglutide given daily for 6 or 14 days prior to whole body, gamma-irradiation significantly increased crypt stem cell survival when compared with vehicle-treated controls.
2 context sentences(design, population, supporting numbers)
Summary · context
The mean levels of protection over a range of doses provided protection factors from 1.3 to 1.5.
Summary · context
A study was initiated to investigate the protective effects of teduglutide on the murine small intestinal epithelium following gamma-irradiation using the crypt microcolony assay as a measure of stem cell survival and functional competence.
Report a problemFND-1554817206
07AnimalAnimal study (in vivo)Efficacy outcome
In mice, teduglutide protection against irradiation was observed only with administration before irradiation.
In plain wordsIn mice, teduglutide protected against radiation only when given before irradiation.
Peptide
Teduglutide
Outcome
Not applicableTiming-dependent protection
Study
mousen: not reported in source
Gamma-irradiated mice
Outcome group
Gastrointestinal protection · Gastrointestinal
Studied dose
Dose not stated
Source sentences
Summary
A protective effect was only observed when teduglutide was given before irradiation.
1 context sentence(design, population, supporting numbers)
Summary · context
A study was initiated to investigate the protective effects of teduglutide on the murine small intestinal epithelium following gamma-irradiation using the crypt microcolony assay as a measure of stem cell survival and functional competence.
Report a problemFND-1554817207

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
28 Oct 2026, 02:03 UTC
Study results updated
Version 1
27 Oct 2026, 16:37 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.